Casirivimab/imdevimab

卡斯瑞韦单抗/依米得韦单抗

Report date: 2022/12/06 15:04:21

Base Information

Drug NameCasirivimab/imdevimab
Drug Alias Nameカシリビマブ（遺伝子組換え）/イムデビマブ（遺伝子組換え）カシリビマブ/イムデビマブREGEN-COVRONAPREVEロナプリーブ +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsRejection of organ transplantationCoronavirus Disease 2019 (COVID-19)Chronic Disease +[4] 
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2021/07/19
Country/TerritoryUnited StatesRomaniaMexico +[9] 
CombinationsYes ImdevimabCasirivimab
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals IncF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharmaceutical Co LtdUniversity Of OxfordRegeneron Pharmaceuticals Inc
Inactive CompaniesNorthwell Health, IncRoche Registration Gmbh
Active IndicationsCoronavirus Disease 2019 (COVID-19)Chronic DiseaseCoronavirus Infections
Inactive IndicationsRejection of organ transplantation

Other Information

ATC CodeD06BB
Related LinksN/A